培美曲塞治疗功能状态评分差的老年晚期肺腺癌患者疗效分析68例

目的观察培美曲塞治疗功能状态评分差的老年晚期肺腺癌患者的临床疗效和毒性反应。方法 68例Ⅳ期肺腺癌患者均经病理组织学和(或)细胞学检查确诊肺腺癌,培美曲塞500mg/m2,每21天重复一次,至少治疗2个周期,重复直至疾病进展或出现不可耐受的毒副作用,培美曲塞治疗后进行评价疗效。结果 68例患者均可评价,总有效率(CR+PR)为39.7%,临床获益率(CR+PR+SD)为72.1%。最主要的毒副反应为白细胞及血小板降低,但均可耐受。结论培美曲塞治疗功能状态评分差的老年晚期肺腺癌有较好疗效,可明显改善患者生存质量,毒副反应较轻,易于耐受。

Clinical Observation of Pemetrexed in Treating Advanced Adenocarcinoma of Lung of Elder Patients and Patients Ineligible for Platinum-Based

Objective To evaluate the clinical effect and toxieity of pemetrexed in treating advanced adenocarcinoma of lung of elder Patients and Patients Ineligible for Platinum-Based.Methods 68 patients with adenocarcinoma of lung diagnosed by pathology or cytology were enrolled into the study.The patients received pemetrexed at a dose of 500 mg/m^2,the chemotherapy was repeated every 21 days on two cycles until progressive disease or untolerant adverse effects.Results Among 17 patients,the overall response rate（CR＋PR） was 39.7%,the clinical benefit rate （CR＋PR＋SD） was 72.1%.The main side effects were leucopenia and thrombocy topenia,but they were tolerable.Conclusion The regimen of pemetrexed plus cisp lation is effective,safe and welltolerable in the treatment of elder adenocarcinoma of lung of elder Patients and Patients Ineligible for Platinum-Based.It significantly prolong the patients,survival time.